Concepedia

Author

J. Y. Han

National Cancer CenterORCID

Also Known As

A. Garcia-Bellido, Cheng, T., Guimaraes Da Costa, J., Han, B-Y, Han, J. Y., J. Han, J. Y. Han, J.-Y. Han, J.Y. Han, Ji Yoon Han

70

Publications

745

Citations

12

H-Index

22

Concepts

All Affiliations

National Cancer CenterSamsung Medical CenterSungkyunkwan UniversitySeoul National University HospitalGuangdong Academy of Medical Sciences
JY

About

J. Y. Han is an author at National Cancer Center specializing in medicine, pharmacotherapy, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

468

2

Health Sciences

2

2

27

3

Gastroenterology

2

2

138

4

Natural Sciences

1

1

15

5

Orthopaedics

1

1

14

J. Y. Han

×

10

Publications

523

Citations

10

H-Index

YearCitations

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

Vassiliki A. Papadimitrakopoulou, Yi‐Long Wu, J. Y. Han,

Annals of Oncology

2018

250

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer

Yong Sang Hong, Si Young Song, S. I. Lee,

Annals of Oncology

2004

124

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

K. Park, J.-S. Lee, J. Y. Han,

Journal of Thoracic Oncology

2016

38

AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)

Caicun Zhou, M. Wang, Ying Cheng,

Annals of Oncology

2018

21

Measurement of Long-Range Near-Side Two-Particle Angular Correlations in p p Collisions at √s = 13 TeV

V. Khachatryan, A. M. Sirunyan, A. Tumasyan,

LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

2016

19

A phase II study of gefitinib as a dirst-line therapy of advanced or metastatic adenocarcinoma of the lung in lifetime non-smokers

D. H. Lee, J. Y. Han, H. G. Lee,

Journal of Clinical Oncology

2005

16

Model-Independent Global Search for New High-pT Physics at CDF

T. Aaltonen, J. Dittmann, A. S. Thompson,

2007

15

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

K. Park, J. Y. Han, D.-W. Kim,

Journal of Thoracic Oncology

2016

15

Successful endoscopic hemoclipping of an esophageal perforation

Hye Young Sung, J. I. Kim, Dae Young Cheung,

Diseases of the Esophagus

2007

14

Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC

Fabrice Barlési, Edward B. Garon, Dongwook Kim,

Annals of Oncology

2016

11

Page 1